How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Topical Imiquimod for the Treatment of Relapsed Cutaneous Langerhans Cell Histiocytosis after Chemotherapy in an Elderly Patient Full Text available with Trip Pro

Topical Imiquimod for the Treatment of Relapsed Cutaneous Langerhans Cell Histiocytosis after Chemotherapy in an Elderly Patient Diagnosis and treatment of Langerhans cell histiocytosis (LCH) in elderly patients are often difficult. We report here a 61-year-old female suffering from a refractory axillary ulcer for nearly a year, whose biopsy revealed LCH. It was also noted that the patient had other cutaneous papulovesicular eruptions of LCH as well as central diabetes insipidus. The patient (...) was first successfully treated with multiagent chemotherapy (cytosine arabinoside/vinblastine/prednisolone). DDAVP also well controlled diabetes insipidus; however, the axillary ulcer and cutaneous LCH relapsed. Thereafter, we found topical imiquimod to be effective in the treatment of relapsed cutaneous LCH lesions.

2018 Case reports in dermatological medicine

42. PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice Full Text available with Trip Pro

PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice Psoriasis is an autoimmune and inflammatory disease, which is estimated to affect 2-3% of the population in the world. PSORI-CM02 is an empirical formula of Chinese medicine optimized from Yin Xie Ling, which is widely used to treat psoriasis in China for decades. However, its antipsoriatic mechanisms are still not well understood. Here, we explored the therapeutic effects (...) of PSORI-CM02 on psoriasis and its mechanisms of action in imiquimod-induced psoriasis-like mouse models and human HaCaT cells. In experiments in vitro, PSORI-CM02 significantly inhibited HaCaT cell proliferation in dose-dependent and time-dependent manners. Furthermore, it hindered the progression of HaCaT cell cycle and arrested HaCaT cells at G1 phase. On the other hand, our in vivo studies demonstrated that PSORI-CM02 dramatically reduced psoriasis area and severity index scores and lesion

2018 Frontiers in immunology

43. Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod Full Text available with Trip Pro

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely (...) investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.

2018 Case reports in oncology

44. Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells Full Text available with Trip Pro

Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells As a topical cancer immunotherapy, the toll-like receptor 7 ligand imiquimod activates tumor regression via stimulation of immune cell infiltration and cytotoxic responses. Imiquimod also exerts direct pro-apoptotic effects on tumor cells in vitro, but a role for these effects in imiquimod-induced tumor regression remains undefined. We (...) previously demonstrated that cell lines derived from devil facial tumor disease (DFTD), a transmissible cancer threatening the survival of the Tasmanian devil (Sarcophilus harrisii), are sensitive to imiquimod-induced apoptosis. In this study, the pro-apoptotic effects of imiquimod in DFTD have been investigated using RNA-sequencing and label-free quantitative proteomics. This analysis revealed that changes to gene and protein expression in imiquimod treated DFTD cells are consistent with the onset

2018 Oncotarget

45. MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease Full Text available with Trip Pro

MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease Persistent activation of mitogen-activated protein kinase (MAPK) is believed to be involved in psoriasis pathogenesis. MAPK phosphatase-1 (MKP-1) is an important negative regulator of MAPK activity, but the cellular and molecular mechanisms of MKP-1 in psoriasis development are largely unknown. In this study, we found that the expression of MKP-1 was decreased in the imiquimod (IMQ)-induced

2018 Frontiers in immunology

46. Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. Full Text available with Trip Pro

Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. Displaying a strong antiproliferative activity on a wide variety of cancer cells, EAPB0203 and EAPB0503 belong to the imidazo[1,2-a]quinoxalines family of imiquimod structural analogues. EAPB0503 has been shown to inhibit tubulin polymerization. The aim of the present study is to characterize the interaction of EAPB0203 (...) to compare the binding site of EAPB0203 and EAPB0503 to known potent tubulin inhibitors. We demonstrate that EAPB0203 and EAPB0503 are capable of blocking human melanoma cells in G2 and M phases and inducing cell death and apoptosis. Second, we show that EAPB0203 and EAPB0503, but also unexpectedly imiquimod, bind directly to purified tubulin and inhibit tubulin polymerization. As suggested by molecular docking and binding competition studies, we identify the colchicine binding site on β-tubulin

2017 PLoS ONE

47. TRPA1 acts in a protective manner in imiquimod-induced psoriasiform dermatitis in mice. Full Text available with Trip Pro

TRPA1 acts in a protective manner in imiquimod-induced psoriasiform dermatitis in mice. This study revealed the modulatory role of transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) cation channels in the Aldara-induced (5% imiquimod) murine psoriasis model using selective antagonists and genetically altered animals. We have also developed a refined localized model to enable internal controls and reduce systemic effects. Skin pathology was quantified by measuring skin (...) thickness, scaling, blood flow, and analyzing dermal cellular infiltrate, whereas nocifensive behaviors were also observed. Cytokine gene expression profiles were measured ex vivo. Psoriasiform dermatitis was significantly enhanced in TRPA1 knockout mice and with TRPA1 antagonist (A967079) treatment. By comparison, symptoms were decreased when TRPV1 function was inhibited. Imiquimod induced Ca2+ influx in TRPA1-, but not in TRPV1-expressing cell lines. Immunohistochemical studies revealed that CD4+ T

2018 Journal of Investigative Dermatology

48. Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice. Full Text available with Trip Pro

Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice. Imiquimod is a Toll-like receptor-7 agonist that regulates immunity and can be used as an immune adjuvant. Ulcerative colitis has a close correlation with immune disorder.To investigate the therapeutic effect of imiquimod on dextran sulfate sodium (DSS)-induced colitis and explore the underlying mechanisms.C57BL/6J C57 mice received 3% DSS for 7 days to induce ulcerative colitis. Groups of mice were (...) intraperitoneally injected with dexamethasone (DXM, 1.5 mg/kg) or imiquimod (IMQ, 30 mg/kg) at the same time daily. During the experimental period, clinical signs, body weight, stool consistency and visible fecal blood were monitored and recorded daily; colitis was evaluated by disease activity index (DAI) score and by histological score. At the conclusion of the experiment, the level of colonic myeloperoxidase (MPO) activity and the serum levels of the cytokines tumor necrosis factor-α (TNF-α), interleukin 6

2017 PLoS ONE

49. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision. Full Text available with Trip Pro

Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision. Staged excision of lentigo maligna (LM) often requires multiple stages and can result in significant cosmetic morbidity. Imiquimod cream has been used off-label as monotherapy in the treatment of LM and may be used in the neoadjuvant setting prior to staged excision as a strategy to reduce the size of the surgical margins required to confirm negative (...) histologic margins.To examine the rate of recurrence of LM in patients treated with neoadjuvant topical imiquimod, 5%, cream prior to conservatively staged excisions.This was a retrospective medical record review of 334 patients with 345 biopsy-confirmed LM tumors from June 2004 to January 2012 who were treated with imiquimod prior to undergoing staged excisions at the University of Utah Medical Center and Huntsman Cancer Institute, large academic hospitals in Salt Lake City.Patients were treated

2018 JAMA dermatology (Chicago, Ill.)

50. Basal cell carcinoma response to imiquimod was associated with the Gli1/Gli3 expression ratio. (Abstract)

Basal cell carcinoma response to imiquimod was associated with the Gli1/Gli3 expression ratio. 30019418 2018 12 03 1365-2133 179 6 2018 Dec The British journal of dermatology Br. J. Dermatol. Response of basal cell carcinoma to imiquimod was associated with the Gli1 : Gli3 expression ratio. 1406-1407 10.1111/bjd.17015 Kanzaki A A Department of Dermatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. Department of Dermatology, Tokyo Medical University, Tokyo, Japan. Kato Y Y http

2018 British Journal of Dermatology

51. Altered expression of Matrix Remodeling Associated 7 (MXRA7) in psoriatic epidermis: evidence for a protective role in the psoriasis imiquimod mouse model. (Abstract)

Altered expression of Matrix Remodeling Associated 7 (MXRA7) in psoriatic epidermis: evidence for a protective role in the psoriasis imiquimod mouse model. Preliminary data mining performed with Gene Expression Omnibus data sets implied that psoriasis may involve the matrix remodelling associated 7 (MXRA7), a gene with little function information yet. To test that hypothesis, studies were performed in human samples and murine models. Immunohistochemistry in normal human skin showed that MXRA7 (...) proteins were present across the full epidermal layer, with highest expression level detected in the basal layer. In psoriatic samples, MXRA7 proteins were absent in the basal stem cells layer, while suprabasal keratinocytes were stained at a higher level than in normal tissues. In an imiquimod-induced psoriasis-like disease model in mice, diseased skins manifested similar MXRA7 expression pattern and change as in human samples, and MXRA7-deficient mice developed severer psoriasis-like diseases than

2018 Experimental Dermatology

52. Is cidofovir a better treatment than imiquimod for high-grade vulval intraepithelial neoplasia? Full Text available with Trip Pro

Is cidofovir a better treatment than imiquimod for high-grade vulval intraepithelial neoplasia? 29453897 2019 02 26 2019 02 26 1471-0528 125 9 2018 08 BJOG : an international journal of obstetrics and gynaecology BJOG Is cidofovir a better treatment than imiquimod for high-grade vulval intraepithelial neoplasia? 1178 10.1111/1471-0528.15170 Helm C William CW Gynaecological Oncology, Princess Alexandra Wing, Royal Cornwall Hospitals Trust, Truro, Cornwall, UK. eng Journal Article Comment 2018 03 (...) 25 England BJOG 100935741 1470-0328 JIL713Q00N Cidofovir P1QW714R7M Imiquimod AIM IM BJOG. 2018 Aug;125(9):1171-1177 29336101 Carcinoma in Situ Cidofovir Female Humans Imiquimod Neoplasm Recurrence, Local Vulvar Neoplasms 2018 2 18 6 0 2019 2 27 6 0 2018 2 18 6 0 ppublish 29453897 10.1111/1471-0528.15170

2018 BJOG

53. 8-Methoxypsoralen Plus Ultraviolet A Reduces the Susceptibility of Murine Skin to Mount a Psoriatic Response to Imiquimod Linked with Senescence and Downregulation of Interleukin-9, 17 and Interferon-gamma. (Abstract)

8-Methoxypsoralen Plus Ultraviolet A Reduces the Susceptibility of Murine Skin to Mount a Psoriatic Response to Imiquimod Linked with Senescence and Downregulation of Interleukin-9, 17 and Interferon-gamma.

2018 Acta Dermato-Venereologica

54. Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. (Abstract)

Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. 29377344 2018 06 26 1468-3083 32 7 2018 Jul Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. e282-e284 10.1111/jdv.14818 Latour I I Hospital Infantil Universitario Niño Jesús, Menéndez Pelayo 65, 28009, Madrid, Spain. Hernández-Martín A A Hospital

2018 Journal of the European Academy of Dermatology and Venereology

55. Resident and monocyte-derived Langerhans cells are required for imiquimod-induced psoriasis-like dermatitis model. Full Text available with Trip Pro

Resident and monocyte-derived Langerhans cells are required for imiquimod-induced psoriasis-like dermatitis model. Langerhans cells (LCs) are dendritic cells that reside in the epidermis and local inflammation results in an increased differentiation of monocyte-derived LCs. Only few studies have investigated on the role of LCs in psoriasis-like dermatitis model, but the results are variable and the exact role of LCs in psoriasis model remains to be elucidated.To explore the functional role (...) of resident (rLCs) and monocyte-derived LCs (mLCs) in imiquimod (IMQ)-induced psoriasis-like inflammation using human Langerin-diphtheria toxin subunit A (huLang-DTA) mice.5% IMQ cream was topically applied on the skins. Clinical and histopathological features were evaluated. Psoriasis-related gene expression was analyzed by quantitative polymerase chain reaction. The production of psoriasis-related cytokines including IL-17A and IL-22 by T cells were assessed by flow cytometry from the lesional

2018 Journal of dermatological science

56. A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-Anal 5% Imiquimod in HIV-1-Infected Men With High-Grade Squamous Intraepithelial Lesions. (Abstract)

A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-Anal 5% Imiquimod in HIV-1-Infected Men With High-Grade Squamous Intraepithelial Lesions. Imiquimod can be used to treat internal anal high-grade squamous intraepithelial lesions. In HIV-1-infected individuals there is a theoretical concern for increased HIV replication in anorectal tissue secondary to imiquimod-induced mucosal inflammation.The purpose of this study was to assess local virologic, immunologic (...) , and pathologic effects of imiquimod treatment in HIV-infected individuals.This was a pilot study at a single academic center.The study was conducted at the University of Pittsburgh Anal Dysplasia Clinic.HIV-1-infected individuals with biopsy-confirmed internal anal high-grade squamous intraepithelial lesions were included.Imiquimod cream was prescribed for intra-anal use 3 times per week for 9 weeks.Anal human papillomavirus typing, anal and rectal tissue HIV-1 RNA and DNA quantification, cytokine gene

2018 Diseases of the Colon & Rectum

57. Management of vulval melanoma in situ with imiquimod. (Abstract)

Management of vulval melanoma in situ with imiquimod. 30430545 2019 01 04 1365-2133 2018 Nov 15 The British journal of dermatology Br. J. Dermatol. Management of vulval melanoma in situ with imiquimod. 10.1111/bjd.17433 Veraitch O O http://orcid.org/0000-0001-9923-1738 St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K. Lewis F F http://orcid.org/0000-0003-4267-1518 St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K

2018 British Journal of Dermatology

58. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: a cohort study. (Abstract)

Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: a cohort study. The effectiveness of 5-fluorouracil compared with that of imiquimod for preventing keratinocyte carcinoma is unknown.To compare the effectiveness of 5-fluorouracil and that of imiquimod in preventing keratinocyte carcinoma in a real-world practice setting.We identified 5700 subjects who filled prescriptions for 5-fluorouracil (...) or imiquimod for treatment of actinic keratosis in 2007. An intention-to-treat analysis controlling for potential confounding variables was used to calculate 2- and 5-year cumulative risk differences for subsequent keratinocyte carcinoma overall and in field-treated areas.5-Fluorouracil was associated with a statistically significant decreased risk of any keratinocyte carcinoma compared with imiquimod (adjusted hazard ratio [aHR], 0.86; 95% confidence interval [CI], 0.76-0.97), but there were

2018 Journal of American Academy of Dermatology

59. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurr Full Text available with Trip Pro

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurr Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual health services in England. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11, and half of episodes diagnosed (...) are recurrences. The best and most cost-effective treatment for patients with anogenital warts is unknown. The commonly used treatments are self-administered topical agents, podophyllotoxin (0.15% cream) or imiquimod (5% cream), or cryotherapy with liquid nitrogen. Quadrivalent HPV (qHPV) vaccination is effective in preventing infection, and disease, but whether it has any therapeutic effect is not known.To investigate the efficacy of clearance and prevention of recurrence of external anogenital warts

2018 BMC Medical Research Methodology Controlled trial quality: uncertain

60. Imiquimod anal tampons treatment of anal intraepithelial neoplasia. (Abstract)

Imiquimod anal tampons treatment of anal intraepithelial neoplasia. 29485187 2018 03 24 1468-3083 2018 Feb 27 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Imiquimod anal tampons treatment of anal intraepithelial neoplasia. 10.1111/jdv.14895 Salas-Márquez C C Área de Dermatología, Hospital Costa del Sol, Marbella, 29603, Spain. Repiso-Jiménez J B JB Área de Dermatología, Hospital Costa del Sol, Marbella, 29603, Spain. Padilla-España L L Área

2018 Journal of the European Academy of Dermatology and Venereology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>